Table 1.
Demographic data and tumor characteristics
| Parameter | n = 73 |
|---|---|
| Gender (M/F) | |
| Male | 63 |
| Female | 10 |
| Age (year)a | 54.9 ± 11.6 (25–79) |
| Etiology | |
| HBV | 55 |
| HCV | 4 |
| Others | 14 |
| Tumor type | |
| Naïve | 19 |
| Recurrent | 54 |
| Surgery history of liver | |
| Yes | 34 |
| No | 37 |
| Liver cirrhosis | |
| Yes | 51 |
| No | 22 |
| Antiviral treatment | |
| Yes | 42 |
| No | 31 |
| ECOG performance status (0/1) | |
| 0 | 71 |
| 1 | 2 |
| Child-Pugh | |
| A | 67 |
| B | 6 |
| Tumor stage of primary HCC | |
| BCLC A | 61 |
| BCLC B | 12 |
| Laboratory data # | |
| AFP (μg/L) | 1021.4 ± 2216.2 (1.85–8034.17) |
| PLT (× 109/L) | 174.1 ± 71.4 (69–345) |
| PT (s) | 12.6 ± 1.1 (10.5–17.1) |
| ALB (g/L) | 40.4 ± 4.8 (27–49.7) |
| ALT (IU/L) | 29.9 ± 16.9 (7–84) |
| TB (mol/L) | 13.6 ± 5.7 (5.4–30.8) |
| Tumor number | |
| Single | 38 |
| Multiple | 33 |
| Location | |
| Paracaval portion | 36 |
| Caudate process | 7 |
| Spiegel’s lobe | 30 |
| Tumor size (cm) | |
| ≤ 2 cm | 32 |
| > 2 cm | 41 |
| Treatment strategy | |
| RFA | 33 |
| EA | 23 |
| RFA-EA | 17 |
| Ablative margin | |
| < 5 mm | 66 |
| ≥ 5 mm | 7 |
HBV hepatitis B virus, HCV hepatitis C virus, ECOG East Coast Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, PLT platelets, PT prothrombin time, ALB albumin, ALT alanine aminotransferase, TB total bilirubin, EA ethanol ablation, RFA radiofrequency ablation, RFA-EA combination of RFA and EA
aData are means ± standard deviations (range)